A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
Clinical trial NCT01668017 · TERMINATED
Trial details
- NCT number
- NCT01668017
- Sponsor
- Merck KGaA, Darmstadt, Germany
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-09-30
- Primary completion
- 2015-05-31
- Enrollment
- 26
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.